clinical trial · NCT06680817
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
Neovascular Age-related Macular DegenerationDiabetic Macular EdemaFaricimab
brief summary
The FaReal study aims to evaluate the effectiveness, safety, clinical insights and treatment patterns in patients treated with faricimab, in neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye, in real-world routine clinical practice over a 2-year patient follow-up period. Additionally, the FaReal study also aims to describe and evaluate health economic aspects of previous anti-VEGF treatments and current treatment with faricimab.
started
Feb 5, 2025
primary completion
Jun 30, 2027
completion
Jun 30, 2028
last updated
Jun 9, 2026
official title
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Faricimab (FaReal Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol